Skip to main content

Table 2 Tumor and patient characteristics of the 67 tumors used for MSI and array CGH analysis.

From: Gastric cancers of Western European and African patients show different patterns of genomic instability

ID gender age Tumor type T N origin MSI status Cluster number Cluster order % events % gains % losses
1 F 62 intestinal T2 N1 Cauc SA MSS 5 34 3.2 3.2 0
2 M 73 intestinal T2 N2 Cauc SA MSS 5 28 16.9 13.4 3.4
3 F 59 intestinal T2 N1 Cauc SA MSS 5 26 26.5 15.1 11.4
4 F 74 intestinal T2 N1 Cauc SA MSS 5 27 15.7 9.3 6.5
5 M 56 intestinal T3 N1 Cauc SA MSI - - 15.6 10.3 5.3
6 M 57 intestinal T2 N1 Cauc SA MSS 6 48 3.4 2.4 1.0
7 F 84 intestinal T1 N0 Cauc SA MSS 6 43 10.9 7.9 3.1
8 F 79 intestinal T3 N0 Cauc SA MSI - - 17.6 16.8 0.8
9 M 68 intestinal T3 N2 Cauc SA MSS 5 25 32.1 24.3 7.7
10 M 65 intestinal T2 N0 native SA MSI - - 1.7 1.7 0
11 M 57 intestinal T1 N0 native SA MSI - - 0 0 0
12 F 29 intestinal T4 N0 native SA MSS 6 37 28.3 26.2 2.1
13 F 59 intestinal T3 N1 native SA MSS 6 42 10.6 5.3 5.3
14 M 66 intestinal T2 N1 native SA MSS 5 31 6.4 6.4 0
15 M 46 intestinal T3 N2 native SA MSS 5 35 3.2 3.2 0
16 F - diffuse T4 N2 native SA MSS 6 44 13.2 12.4 0.7
17 M 51 intestinal T3 N1 native SA MSS 5 32 6.1 6.1 0
18 F 49 intestinal T3 N1 native SA MSS 4 20 29.1 18.2 10.9
19 M 56 intestinal T3 N1 native SA MSS 4 19 26.0 10.3 15.7
20 M 48 intestinal T3 N2 native SA MSS 5 36 5.4 5.4 0
21 M 65 mixed T3 N1 native SA MSI - - 18.2 16.3 1.9
22 M 60 intestinal T2 - native SA MSS 6 41 14.0 11.3 2.7
23 F 63 intestinal - - native SA MSS 6 38 17.1 10.7 6.4
24 F 54 papillary T2 N0 native SA MSS 3 14 44.8 20.6 24.2
25 M 67 intestinal T3 N1 native SA MSS - - - - -
26 M 31 intestinal T3 N1 native SA MSS 5 24 41.1 28.4 12.7
27 M 43 intestinal T3 N1 native SA MSI - - 9.9 9.9 0
28 F 71 intestinal T3 - native SA MSS 5 33 3.7 2.7 1.0
29 F 77 intestinal T3 N1 native SA MSS 5 30 12.7 7.1 5.5
30 M 57 intestinal T2 N0 native SA MSS - - - - -
31 M 79 intestinal T3 N2 native SA MSI - - 2.5 2.5 0
32 M 57 intestinal T4 N0 native SA MSI - - 17.8 16.8 1.0
33 M 56 mixed T3 N1 native SA MSS 4 17 42.2 21.3 20.9
34 F 49 mixed T3 N3 native SA MSS 5 29 22.3 19.2 3.2
35 F 82 diffuse T1 N0 UK MSS 6 46 11.2 10.3 1.0
36 M 81 diffuse T3 N2 UK MSS 4 22 15.7 7.2 8.5
37 M 71 diffuse T2 N1 UK MSS 7 53 18.4 14.7 3.7
38 M 73 intestinal T2 N0 UK MSS 2 11 26.0 17.2 8.8
39 F 65 diffuse T2 N3 UK MSS 6 45 15.0 12.0 3.1
40 F 58 diffuse T3 N3 UK MSS 1 6 25.7 13.7 12.0
41 F 51 diffuse T3 N3 UK MSS 1 7 22.4 16.5 6.0
42 M 91 intestinal T1 N0 UK MSS 7 56 49.2 27.6 21.6
43 M 71 diffuse T3 N2 UK MSS 7 49 40.6 19.8 20.8
44 M 73 intestinal T2 N1 UK MSS 1 5 21.0 8.2 12.9
45 M 64 diffuse T2 N0 UK MSS 7 50 14.9 10.3 4.6
46 F 71 intestinal T1 N0 UK MSS 1 4 40.8 13.4 27.4
47 F 60 intestinal T4 N1 UK MSS 3 16 30.1 15.6 14.5
48 F 96 diffuse T3 N0 UK MSS 2 12 41.0 25.0 16.0
49 M 91 mixed T3 N0 UK MSS 6 40 16.0 11.4 4.6
50 M 81 diffuse T2 N0 UK MSS 2 10 37.7 17.2 20.4
51 F 83 intestinal T2 N0 UK MSS 7 51 14.5 10.5 4.0
52 F 82 intestinal T3 N1 UK MSS 6 47 2.2 2.2 0
53 F 77 intestinal T3 N1 UK MSS 6 39 19.5 11.1 8.5
54 M 74 mixed T2 N1 UK MSS 2 8 44.8 22.4 22.3
55 F 59 diffuse T3 N1 UK MSS 3 15 26.4 18.1 8.2
56 M 77 mixed T3 N2 UK MSS 1 3 24.1 13.7 10.3
57 M 75 intestinal T2 N0 UK MSS 2 9 36.9 18.2 18.7
58 M 64 diffuse T3 N3 UK MSS 2 13 35.3 20.2 15.1
59 M 71 intestinal T3 N1 UK MSS 1 2 31.0 11.7 19.3
60 F 74 diffuse T3 N2 UK MSS 4 23 23.2 14.7 8.4
61 M 81 intestinal T2 N0 UK MSI - - 10.7 8.7 2.0
62 F 74 mixed T3 N2 UK MSS 4 18 30.4 17.9 12.5
63 M 67 mixed T3 N1 UK MSS 7 52 12.3 6.4 5.9
64 M 73 intestinal T3 N1 UK MSS 4 21 15.2 7.3 7.9
65 F 66 mixed T3 N2 UK MSS 7 55 34.3 18.7 15.6
66 M 82 intestinal T1 N1 UK MSS 7 54 46.7 27.4 19.3
67 F 62 mixed T3 N0 UK MSS 1 1 44.0 20.7 23.3
  1. Percentages of events, gains and losses are given for all tumors of sufficient array CGH quality. Cluster number and order are listed for the 56 cases included in the cluster analysis.
  2. F: female, M: male, T: T-stage, N: N-stage MSS: microsatellite stable, MSI: microsatellite instable, Cauc SA: Caucasian South African patients, native SA: native South African patients, UK: patients from United Kingdom, -: unknown.